Pieris Pharmaceuticals Investor Relations Material

Pieris Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on the discovery and development of Anticalin-based therapies, which are engineered proteins designed to treat respiratory diseases, cancer, and other conditions. The company’s proprietary Anticalin platform allows for the creation of novel biologics that target specific disease pathways. Pieris is developing a pipeline of therapies for immuno-oncology, asthma, and other respiratory conditions, working both independently and through collaborations with pharmaceutical partners. The company is headquartered in Boston, Massachusetts, and its shares are listed on the Nasdaq.